Lixte Biotechnology Holdings, Inc.

Filed Date	Form Type	Description	View
06/24/2022	Form 8-K	Current Report
06/23/2022	Form 8-K	Current Report
06/17/2022	Form 8-K	Current Report
05/13/2022	Form 8-K	Current Report
05/11/2022	Form 10-Q	Quarterly Report
04/15/2022	Form 8-K	Current Report
04/14/2022	Form 424B5	Prospectus [Rule 424(b)(5)]
04/07/2022	Form SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
04/07/2022	Form SC 13G	Statement of acquisition of beneficial ownership by individuals
04/06/2022	Form 4	Initial statement of beneficial ownership of securities
04/06/2022	Form 3	Initial statement of beneficial ownership of securities
03/23/2022	Form 8-K	Current Report
03/21/2022	Form 10-K	Annual Report
02/14/2022	Form 5	Annual statement of changes in beneficial ownership of securities
01/04/2022	Form SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
11/10/2021	Form 10-Q	Quarterly Report
10/13/2021	Form 8-K	Current Report
09/20/2021	Form 424B5	Prospectus [Rule 424(b)(5)]
09/20/2021	Form 8-K	Current Report
08/10/2021	Form 10-Q	Quarterly Report
07/09/2021	Form 8-K	Current Report
07/02/2021	Form 4	Statement of changes in beneficial ownership of securities
07/02/2021	Form 4	Statement of changes in beneficial ownership of securities
07/02/2021	Form 4	Statement of changes in beneficial ownership of securities
07/02/2021	Form 4	Statement of changes in beneficial ownership of securities
07/02/2021	Form 4	Statement of changes in beneficial ownership of securities
06/03/2021	Form 8-K	Current Report
05/25/2021	Form DEFA 14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material
05/25/2021	Form DEF14A	Other definitive proxy statements
05/14/2021	Form 8-K	Current Report
05/14/2021	Form 3	Initial Statement of Beneficial Ownership of Securities
05/13/2021	Form PRE 14A	Other preliminary proxy statements
05/12/2021	Form 10-Q	Quarterly Report
04/26/2021	Form 4	Statement of changes in beneficial ownership of securities
04/26/2021	Form 4	Statement of changes in beneficial ownership of securities
04/26/2021	Form 4	Statement of changes in beneficial ownership of securities
04/21/2021	Form S-8	Securities to be offered to employees in employee benefit plans
04/15/2021	Form 4	Statement of changes in beneficial ownership of securities
04/13/2021	Form 8-K	Current Report
03/26/2021	Form 10-K	Annual Report
03/03/2021	Form SC 13G	Statement of acquisition of beneficial ownership by individuals
03/02/2021	Form 8-K	Current Report
03/01/2021	Form 424B5	Prospectus [Rule 424(b)(5)]
02/05/2021	Form EFFECT	Notice of Effectiveness
01/26/2021	Form S-3	Registration statement under Securities Act of 1933
01/22/2021	Form 8-K	Current Report
01/14/2021	Form 4	Statement of changes in beneficial ownership of securities
01/14/2021	Form 4	Statement of changes in beneficial ownership of securities
01/14/2021	Form 4	Statement of changes in beneficial ownership of securities
01/14/2021	Form 4	Statement of changes in beneficial ownership of securities
01/05/2021	Form 4	Statement of changes in beneficial ownership of securities
01/04/2021	Form 4	Statement of changes in beneficial ownership of securities
12/17/2020	Form SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
12/17/2020	Form SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
12/17/2020	Form SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
12/17/2020	Form SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
12/17/2020	Form SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
12/09/2020	Form 4	Statement of changes in beneficial ownership of securities
12/07/2020	Form 4	Statement of changes in beneficial ownership of securities
12/04/2020	Form 4	Statement of changes in beneficial ownership of securities
12/03/2020	Form 4	Statement of changes in beneficial ownership of securities
12/03/2020	Form 4	Statement of changes in beneficial ownership of securities
12/03/2020	Form 4	Statement of changes in beneficial ownership of securities
12/02/2020	Form 4	Statement of changes in beneficial ownership of securities
12/02/2020	Form 8-K	Current Report
11/27/2020	Form 424B4	Prospectus filed pursuant to Rule 424(b)(4)
11/27/2020	Form 8-K	Current Report
11/24/2020	Form EFFECT	Notice of Effectiveness
11/18/2020	Form CERT	Certification
11/17/2020	Form 8-A12B	Registration of securities [Section 12(b)]
11/16/2020	Form S-1/A	[Amend] General form for registration of securities under the Securities Act of 1933
11/10/2020	Form 10-Q	Quarterly Report
11/02/2020	Form S-1/A	[Amend] General form for registration of securities under the Securities Act of 1933
10/13/2020	Form S-1/A	[Amend] General form for registration of securities under the Securities Act of 1933
09/03/2020	Form S-1	General form for registration of securities under the Securities Act of 1933
08/31/2020	Form DEF 14C	Definitive Information Statements
08/20/2020	Form 3	Initial Statement of Beneficial Ownership of Securities
08/18/2020	Form 8-K	Current Report
08/11/2020	Form PRE14C	Other preliminary information statements
08/10/2020	Form 10-Q	Quarterly Report
07/17/2020	Form 8-K	Current Report
07/17/2020	Form 8-K	Current Report
05/11/2020	Form 10-Q	Quarterly Report
03/25/2020	Form 10-K	Annual Report
11/08/2019	Form 10-Q	Quarterly Report
09/19/2019	Form CT ORDER	Confidential treatment order
08/06/2019	Form 10-Q	Quarterly Report
08/06/2019	Form 8-K	Current Report
05/09/2019	Form 10-Q	Quarterly Report
03/25/2019	Form 10-K	Annual Report
12/12/2018	Form D	Notice of Exempt Offering of Securities
12/11/2018	Form 4	Statement of changes in beneficial ownership of securities
12/11/2018	Form 4	Statement of changes in beneficial ownership of securities
12/11/2018	Form 4	Statement of changes in beneficial ownership of securities
12/11/2018	Form 4	Statement of changes in beneficial ownership of securities
12/11/2018	Form 3	Initial Statement of Beneficial Ownership of Securities
12/05/2018	Form 8-K	Current Report
11/08/2018	Form 10-Q	Quarterly Report
11/07/2018	Form 8-K	Current Report
09/17/2018	Form CT ORDER	Confidential treatment order
08/23/2018	Form 8-K	Current Report
08/14/2018	Form 3	Initial Statement of Beneficial Ownership of Securities
08/14/2018	Form 3	Initial Statement of Beneficial Ownership of Securities
08/09/2018	Form 8-K	Current Report
08/02/2018	Form 10-Q	Quarterly Report
04/27/2018	Form 10-Q	Quarterly Report
03/23/2018	Form 10-K	Annual Report
11/09/2017	Form 10-Q	Quarterly Report
08/04/2017	Form 10-Q	Quarterly Report
05/10/2017	Form 10-Q	Quarterly Report
04/26/2017	Form SC 13G	Statement of acquisition of beneficial ownership by individuals
04/17/2017	Form 3	Initial Statement of Beneficial Ownership of Securities
04/13/2017	Form SC 13G	Statement of acquisition of beneficial ownership by individuals
04/10/2017	Form 8-K	Current Report
03/29/2017	Form 10-K	Annual Report
02/28/2017	Form 8-K	Current Report
01/12/2017	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
01/12/2017	Form 4	Statement of changes in beneficial ownership of securities
12/29/2016	Form 8-K	Current Report
11/28/2016	Form 8-K	Current Report
11/04/2016	Form 10-Q	Quarterly Report
08/10/2016	Form 10-Q	Quarterly Report
06/07/2016	Form 3	Initial statement of beneficial ownership of securities
06/07/2016	Form 4	Statement of changes in beneficial ownership of securities
05/17/2016	Form 8-K	Current Report
05/06/2016	Form10-Q	Quarterly Report
03/28/2016	Form 10-K	Annual Report
02/19/2016	Form 4	Statement of Changes in Beneficial Ownership of Securities
02/04/2016	Form 4	Statement of Changes in Beneficial Ownership of Securities
02/03/2016	Form 8-K	Current Report
01/26/2016	Form 8-K	Current Report
01/22/2016	Form 4	Statement of Changes in Beneficial Ownership of Securities
01/22/2016	Form SC 13G/A	[Amend] Statement of Acquisition of Beneficial Ownership by Individuals
12/30/2015	Form 8-K	Current Report
11/10/2015	Form 10-Q	Current Report
11/10/2015	Form 8-K	Current Report
09/18/2015	Form 8-K	Current Report
09/04/2015	Form SC 13G	Statement of Acquisition of Beneficial Ownership by Individuals
09/03/2015	Form 3	Initial Statement of Beneficial Owenership of Securities
09/03/2015	Form 3	Initial Statement of Beneficial Owenership of Securities
08/07/2015	Form 10-Q	Quarterly Report
08/06/2015	Form SC 13D	General Statement of Acquisition of Beneficial Ownership
08/05/2015	Form 4	Statement of Changes in Beneficial Ownership of Securities
06/05/2015	Form SC 13G/A	[Amend] Statement of Acquisition of Beneficial Ownership by Individuals
05/13/2015	Form 10-Q	Quarterly Report
03/27/2015	Form 10-K	Annual Report
03/19/2015	Form 4	Statement of Changes in Beneficial Ownership of Securities
03/19/2015	Form 4	Statement of Changes in Beneficial Ownership of Securities
03/18/2015	Form 8-K	Current Report
03/04/2015	Form 8-K	Current Report
01/23/2015	Form 8-K	Current Report
11/12/2014	Form 10-Q	Quarterly Report
08/08/2014	Form 10-Q	Quarterly Report
05/21/2014	Form SC 13G	Statement of acquisition of beneficial ownership by individuals
05/21/2014	Form 3	Statement of acquisition of beneficial ownership by individuals
05/14/2014	Form 4	Statement of Changes in Beneficial Ownership of Securities
05/14/2014	Form 4	Statement of Changes in Beneficial Ownership of Securities
05/12/2014	Form SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
05/12/2014	Form SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
05/09/2014	Form 10-Q	Quarterly Report
04/18/2014	Form 8-K	Current Report
03/21/2014	Form 10-K	Annual Report
11/13/2013	Upload	SEC-Generated Letter
11/07/2013	Form 10-Q	Quarterly Report
10/08/2013	Corresp	Correspondence
09/30/2013	Corresp	Correspondence
09/16/2013	Upload	SEC-Generated Letter
08/05/2013	Form 10-Q	Quarterly Report
05/09/2013	Form 10-Q	Quarterly Report
03/15/2013	Form 10-K	Annual Report
03/14/2013	Form SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals

Recent Financial News for LIXT Headline LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF BAS VAN DER BAAN, INTERNATIONALLY RECOGNIZED BIOTECH BUSINESS DEVELOPMENT EXECUTIVE, TO ITS BOARD OF DIRECTORS GlobeNewswire (Jun 21, 2022) LIXTE BIOTECHNOLOGY ANNOUNCES APPOINTMENT OF PROFESSOR RENÉ BERNARDS TO ITS BOARD OF DIRECTORS GlobeNewswire (Jun 15, 2022) LIXTE Biotechnology Announces the Closing of $5.8 Million Registered Direct Offering Priced At-The-Market GlobeNewswire (Apr 14, 2022) LIXTE Biotechnology Announces $5.8 Million Registered Direct Offering Priced At-The-Market GlobeNewswire (Apr 12, 2022) LIXTE Biotechnology Announces Preclinical Results of its Collaboration with the Netherlands Cancer Institute, Revealing Striking Anti-Cancer Activity of LB-100 In Novel Drug Combinations GlobeNewswire (Apr 12, 2022) Inactivating Mutations in Scaffold Component of PP2A, the Target Enzyme of LIXTE Biotechnology’s Clinical Compound LB-100, are Associated with Exceptionally Long Survival of Patients with Ovarian Clear Cell Cancer Treated with Immunotherapy GlobeNewswire (Mar 22, 2022) LIXTE Biotechnology Holdings, Inc. to Present at MedInvest Pharmaceutical and Biotechnology Investor Conference GlobeNewswire (Mar 16, 2022) Lixte Biotechnology Announces Filing of First Patent Application Resulting from Collaboration with the Netherlands Cancer Institute and the Oncode Institute to Identify the Most Promising Drug Combinations for Lead Clinical Compound, LB-100 GlobeNewswire (Jan 12, 2022) Lixte Biotechnology’s LB-100 Reported to Convert Immunologically Unresponsive (“Cold”) Tumors to Immunologically Responsive (“Hot”) Tumors GlobeNewswire (Jan 05, 2022) LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THAT ENROLLMENT HAS RESUMED IN NATIONAL CANCER INSTITUTE’S TRIAL TO DETERMINE ABILITY OF LIXTE COMPOUND LB-100 TO ENTER RECURRENT, MALIGNANT BRAIN TUMORS GlobeNewswire (Nov 22, 2021) Lixte Biotechnology to Discuss its Collaboration with Leading European Cancer Centers at the Benzinga Global Small Cap Conference on October 28 GlobeNewswire (Oct 20, 2021) Lixte Biotechnology Announces Collaboration with Netherlands Cancer Institute (Amsterdam) and Oncode Institute (Utrecht) to Identify the Most Promising Drug Combinations for its Lead Clinical Compound, LB-100, for Cancer Treatment GlobeNewswire (Oct 13, 2021) Lixte Biotechnology’s LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine Addiction GlobeNewswire (Aug 17, 2021) LIXTE BIOTECHNOLOGY’S LB-100 ELICITS ANTI- TUMOR ACTIVITY IN SMALL LUNG CANCER MODELS BY UNIQUE MECHANISMS IN AN IMPORTANT PRE-CLINICAL STUDY GlobeNewswire (Aug 03, 2021) LIXTE BIOTECHNOLOGY COMMENTS ON REPORT THAT ITS PP2A INHIBITOR LB-100 COMBINED WITH ANOTHER INVESTIGATIONAL AGENT STIMULATES BONE GROWTH IN MODELS OF DWARFISM GlobeNewswire (Jul 22, 2021) Lixte Biotechnology Comments on Outside Research Citing LB-100’s PP2A Inhibition as a Potential Therapeutic Strategy for Triple-Negative Breast Cancer GlobeNewswire (Jul 13, 2021) Lixte Biotechnology to Present its Drug Development Pipeline for Cancer Treatment at The MoneyShow Virtual Expo on July 14, 2021 GlobeNewswire (Jul 07, 2021) Lixte Biotechnology and City of Hope Enroll First Patient in Phase 1b Trial of Lead Compound LB-100 for Treatment of Small Cell Lung Cancer GlobeNewswire (Jun 02, 2021) LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THE APPOINTMENT OF REGINA BROWN TO ITS BOARD OF DIRECTORS GlobeNewswire (May 12, 2021) Lixte Biotechnology to Present Key Advantages of Novel Cancer Drug Candidate LB-100 at the Sidoti Virtual Microcap Conference on May 20 GlobeNewswire (May 04, 2021) Lixte Biotechnology to Discuss Pipeline of Clinical Investigations for Four Cancer Targets at the Benzinga Global Small Cap Conference Being Held May 13-14 GlobeNewswire (Apr 28, 2021) Lixte Biotechnology Holdings, Inc. Announces the Appointment of Gil N Schwartzberg to its Board of Directors GlobeNewswire (Apr 13, 2021) Lixte Biotechnology to Present Its Novel Product Candidate for Targeted Cancer Therapy at the Benzinga Biotech Small Cap Conference on March 24 GlobeNewswire (Mar 17, 2021) Lixte Biotechnology to Showcase Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual 33rd Annual ROTH Capital Conference GlobeNewswire (Mar 03, 2021) Lixte Biotechnology Announces the Closing of $4.19 Million Registered Direct Offering GlobeNewswire (Mar 02, 2021) Lixte Biotechnology Announces $4.19 Million Registered Direct Offering GlobeNewswire (Mar 01, 2021) Lixte Biotechnology to Present Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual H.C. Wainwright Global Life Sciences Conference GlobeNewswire (Feb 24, 2021) Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte’s Lead Compound LB-100 to Treat Small Cell Lung Cancer GlobeNewswire (Jan 19, 2021) Lixte Biotechnology Holdings, Inc. Announces Closing of Public Offering and Uplisting to Nasdaq GlobeNewswire (Dec 01, 2020) Lixte Biotechnology Holdings, Inc. Announces Pricing of $5,700,000 Public Offering; Uplisting to Nasdaq Capital Market and Reverse Stock Split GlobeNewswire (Nov 25, 2020) The Foundation for Angelman Syndrome Therapeutics (FAST) and Lixte Biotechnology Collaborate to Support the Preclinical Study of Lixte’s Protein Phosphatase 2A Inhibitor, LB-100, as a Possible Treatment for Angelman Syndrome GlobeNewswire (Aug 18, 2020) Lixte Biotechnology Holdings, Inc. Announces The Appointment Of Internationally Recognized Clinical Cancer Investigator, James S. Miser MD, As Chief Medical Officer GlobeNewswire (Jul 21, 2020) Lixte Biotechnology’s PP2A Inhibitor, LB-100, Enhances the Effectiveness of PD1 Immune Blockade in Mouse Models of Glioblastoma Brain Tumors GlobeNewswire (Apr 30, 2020) First Two Patients Enrolled in National Cancer Institute Trial of the Ability of Lixte Biotechnology's LB-100 to Enter Recurrent Malignant Brain Tumors GlobeNewswire (Dec 04, 2019) The Spanish Sarcoma Group Will Lead a European Consortium to Evaluate the Ability of Lixte Biotechnology Holdings' LB-100 to Improve First Line Therapy for Advanced Soft Tissue Sarcomas GlobeNewswire (Aug 06, 2019) The Spanish Sarcoma Group Will Lead a European Consortium to Evaluate the Ability of Lixte Biotechnology Holdings' LB-100 to Improve First Line Therapy for Advanced Soft Tissue Sarcomas GlobeNewswire (Aug 06, 2019) First Patient Enrolled in Phase 1b/2 Trial of Lixte Biotechnology's LB-100 in Low or Intermediate-1 Risk Myelodysplastic Syndrome GlobeNewswire (Jul 18, 2019) Lixte Biotechnology's PP2A Inhibitor, LB-100, Improves Brain Function and Motor Impairment in a Mouse Model of Angelman Syndrome, a Rare Human Neurodevelopmental Disorder GlobeNewswire (Jun 25, 2019) Lixte Biotechnology's LB-100 to be Evaluated by the National Cancer Institute in a Clinical Study of LB-100's Ability to Enter Recurrent Glioblastoma Multiforme Brain Tumors GlobeNewswire (May 15, 2019) FDA Approves Lixte Biotechnology's IND to Conduct a Phase 1b/2 Trial of LB-100 in Patients with Myelodysplastic Syndrome at Moffitt Cancer Center GlobeNewswire (Nov 05, 2018) Lixte Biotechnology Files an IND with the FDA to Conduct a Phase 1b/2 Trial of LB-100 in Patients with Myelodysplastic Syndrome at Moffitt Cancer Center GlobeNewswire (Oct 09, 2018) Lixte Biotechnology Announces a Clinical Trial Agreement with Moffitt Cancer Center to Initiate Phase 1b/2 Trial Evaluating the Safety and Efficacy of LB-100 in Treatment of Patients with Low or Intermediate-1 Risk Myelodysplastic Syndrome GlobeNewswire (Aug 21, 2018) Yun Yen, MD, PhD and Winson (Sze Chun) Ho, MD Join Lixte Biotechnology's Board of Directors GlobeNewswire (Aug 08, 2018) LB-100 and LB-102, Lixte Biotechnology's Protein Phosphatase 2A Inhibitors, Sensitize BCR-ABL Leukemia Stem Cells to Targeted Therapy with Tyrosine Kinase Inhibitors GlobeNewswire (Feb 09, 2018) Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, LB-100, Reported to be a Potentiator of Immunotherapy in an Animal Model Marketwired (Apr 17, 2017) Late-Breaking Abstract on LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, in Combination with a PD-1 Inhibitor in an Animal Model to be Presented at the AACR Annual Meeting Marketwired (Mar 09, 2017) First-In-Human Assessment of LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, Published in Clinical Cancer Research Marketwired (Jan 04, 2017) Dr. Stephen Forman Joins Lixte Biotechnology's Board of Directors Marketwired (Jun 07, 2016) Lixte Biotechnology Holdings, Inc.'s Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depression Marketwired (Feb 03, 2016) Lixte Completes Private Placement of Convertible Preferred Stock Marketwired (Jan 25, 2016) Lixte Biotechnology Holdings, Inc. Announces Exclusive Licensing Of Their Lead Anti-Cancer Compound LB-100 For Potential Treatment Of Hepatocellular Carcinoma In Asia To Taipei Medical University PRNewswire (Dec 30, 2015) Lixte Biotechnology Holdings, Inc. Announces That Its Novel Protein Phosphatase 2A Inhibitor Is Associated With Stabilization Of Several Types Of Cancer Without Dose-Limiting Toxicity PRNewswire (Nov 06, 2015) Lixte Biotechnology Holdings, Inc. Engages BioPharmaWorks LLC To Enhance Development Of Its Pipeline Of Novel Compounds PRNewswire (Sep 17, 2015) Lixte Biotechnology to Obtain High-Quality Tissue and Blood Samples from German University PRIME NEWSWIRE (Jan 11, 2007)